BRCA2 and neoplasm: As observed in ovarian and breast tumours, targeting poly (ADP-ribose) polymerase 1 (PARP1) in tumours with BRCA1 and breast cancer gene 2 (BRCA2) inactivation selectively causes cancer cell death, showing promise in clinical settings [14, 15].